Comparative Pharmacology
Head-to-head clinical analysis: INFLAMASE FORTE versus PREDSULFAIR II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFLAMASE FORTE versus PREDSULFAIR II.
INFLAMASE FORTE vs PREDSULFAIR II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Prednisolone is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators. Sulfonamide component provides bacteriostatic action via inhibition of dihydropteroate synthase in bacterial folate synthesis.
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
1-2 drops into the affected eye(s) every 4-6 hours; not to exceed 6 doses per day.
None Documented
None Documented
Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life of prednisolone (active moiety): 2.1-3.5 hours; clinical context: duration of HPA axis suppression exceeds plasma half-life (12-36 hours).
Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination.
Renal: 70-80% (30-50% as unchanged prednisolone, 20-30% as prednisone and inactive metabolites); Biliary/Fecal: 15-20%
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Sulfonamide Combination